Despite sales dive, Moderna ups full-year outlook

4 August 2023

Like other pharma majors that achieved huge sales and profits at the height of related to the COVID-19 pandemic, which has since subsided, pioneering US mRNA company Moderna (Nasdaq: MRNA) reported a massive decline in second-quarter 2023 revenues. Moderna’s shares were up 5% pre-market but closed virtually unchanged.

Total revenue for the second quarter of 2023 was $344 million, compared to $4.7 billion in the same period in 2022, mainly due to a decrease in sales of the company's COVID-19 vaccine, trade named Spikevax and Moderna’s only currently approved product. The figure was higher than Bloomberg estimates of $321.8 million. Product sales for the second quarter of 2023 were $293 million, a decrease of 94%, primarily driven by lower sales volume.

Net loss was $1.4 billion, compared to net income of $2.2 billion for the second quarter of 2022. Diluted loss per share was $3.62, compared to diluted earnings per share (EPS) of $5.24 for the second quarter of 2022, although this was still narrower than estimates for a $4.04 loss.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK